Literature DB >> 2968800

Inhibition by suramin of mitochondrial ATP synthesis.

N B Calcaterra1, L R Vicario, O A Roveri.   

Abstract

Suramin, a drug intensively used in the chemotherapy of African trypanosomiasis and onchocerciasis, is currently being tested in clinical trials for AIDS treatment. Its effects on mitochondrial energy metabolism in mammals were studied. At low concentrations it inhibited ATP synthesis and ATPase activity in submitochondrial particles, as well as ADP-stimulated oxygen consumption and the uncoupler-stimulated ATPase activity in intact rat liver mitochondria. At higher concentrations it also inhibited uncoupled electron transport in both submitochondrial particles and intact mitochondria. From comparison of the kinetic patterns of those inhibitions, evidence suggesting that the adenine nucleotide translocase may be another target for the action of suramin was obtained. The relevance of these findings to the understanding of the biochemical basis of suramin toxicity is discussed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2968800     DOI: 10.1016/0006-2952(88)90241-9

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  5 in total

1.  Effects of the P2-purinoceptor antagonist, suramin, on human platelet aggregation induced by adenosine 5'-diphosphate.

Authors:  S M Hourani; D A Hall; C J Nieman
Journal:  Br J Pharmacol       Date:  1992-02       Impact factor: 8.739

Review 2.  Suramin: an anticancer drug with unique biological effects.

Authors:  A K Larsen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  Suramin antagonizes responses to P2-purinoceptor agonists and purinergic nerve stimulation in the guinea-pig urinary bladder and taenia coli.

Authors:  C H Hoyle; G E Knight; G Burnstock
Journal:  Br J Pharmacol       Date:  1990-03       Impact factor: 8.739

4.  High-throughput screening of FDA-approved drugs using oxygen biosensor plates reveals secondary mitofunctional effects.

Authors:  Sunil Sahdeo; Alexey Tomilov; Kelly Komachi; Christine Iwahashi; Sandipan Datta; Owen Hughes; Paul Hagerman; Gino Cortopassi
Journal:  Mitochondrion       Date:  2014-07-14       Impact factor: 4.160

5.  Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study.

Authors:  M A Villalona-Calero; G A Otterson; M G Wientjes; F Weber; T Bekaii-Saab; D Young; A J Murgo; R Jensen; T-K Yeh; Y Wei; Y Zhang; C Eng; M Grever; J L-S Au
Journal:  Ann Oncol       Date:  2008-07-15       Impact factor: 32.976

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.